EP2001555A1 - Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer - Google Patents

Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer

Info

Publication number
EP2001555A1
EP2001555A1 EP07727390A EP07727390A EP2001555A1 EP 2001555 A1 EP2001555 A1 EP 2001555A1 EP 07727390 A EP07727390 A EP 07727390A EP 07727390 A EP07727390 A EP 07727390A EP 2001555 A1 EP2001555 A1 EP 2001555A1
Authority
EP
European Patent Office
Prior art keywords
membered
radicals
alkyl
och
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07727390A
Other languages
German (de)
English (en)
Inventor
Bennard Van Ravenzwaay
Werner Mellert
Georgia Coelho Palermo Cunha
Klaus Deckardt
Heinz Kieczka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2001555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE filed Critical BASF SE
Priority to EP07727390A priority Critical patent/EP2001555A1/fr
Publication of EP2001555A1 publication Critical patent/EP2001555A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • the present invention relates to the treatment and prevention of disorders of iron metabolism by the use of strobilurins and their synthetic analogs.
  • Iron is a widely used element in nature, which can be detected in almost all cells of the animal and plant organism. As an essential trace element, iron and its compounds play an important role in the healthy nutrition of mammals as well as humans. In nature, in humans and animals, as well as in plants, different iron deficiency diseases occur, but also disorders of the iron balance are observed based on an increased iron level. In the field of veterinary medicine and human nutrition, iron-deficiency diseases can be overcome by the administration of iron preparations, which usually contain iron in the form of iron (M) or iron (IM) compounds.
  • M iron
  • IM iron
  • iron (M) in humans and animals is absorbed mainly in the duodenum. Iron (IM) is usually first reduced and then reabsorbed. In the human body, about two-thirds of iron is bound to hemoglobin, while one-third of iron is stored in the form of other proteins, such as myoglobin or ferritin. While much of the iron needs of humans and animals can already be met by recycling iron released during the breakdown of hemoglobin, the remaining hemoglobin must be supplied through the diet.
  • iron compounds not only have a corrosive effect, but can also cause mucous membrane irritation and acute toxicity in higher doses.
  • Exceeding the binding capacity of the storage proteins in the blood can lead to severe symptoms of intoxication.
  • the underlying cell damage in the gastrointestinal tract as well as in the liver can be attributed, inter alia, to the radical formation from water and oxygen by the transition metal ions. explain iron (II) and iron (IM).
  • II iron
  • IM iron
  • the hydroxyl radicals react with various organic molecules in the cell and lead to severe damage or destruction of entire organs.
  • the acute-toxic dose (LD 50) is approximately 700 mg / kg body weight for example for iron (II) sulfate in the mouse, approximately 300 mg / kg body weight in the rat and approximately 600 mg / kg body weight in the rabbit.
  • the typical symptoms of intoxication include, in particular, the gastrointestinal tract (for example intestinal bleeding and diarrhea), the urinary tract (discolouration of the urine), the cardiovascular system (for example metabolic acidosis and circulatory shock) and the skin (mucosal changes, edema).
  • the symptomatic treatment of the frequently occurring circulatory and respiratory problems is in the foreground; on the other hand, the iron levels can be reduced by the administration of a suitable antidote. be graced.
  • a suitable antidote for example, the chelating agent deferoxamine mesylate is used in clinical practice, which can be administered intravenously at a dose of up to 80 mg / kg per day, but care must be taken to ensure strict adherence to a low infusion rate.
  • An object of the present invention was to provide more effective, more practicable and side effect less treatment methods in disorders of iron metabolism.
  • Strobilurins have been known as natural products for decades. They are produced in nature by fungi of the genus Strobilurus, but can also be produced synthetically well. Since the naturally occurring strobulin A easily decomposes under the influence of light, numerous derivatives have been synthesized in recent years, some of which have found commercial use as active ingredients in fungicide preparations.
  • Strobulins have so far been used for the preventive control of harmful fungi in various cereals. They work in the mitochondria and interfere with the process of cellular respiration, leading to an interruption of the electron transport in the respiratory chain.
  • EP-A 477631, WO 97/15552 and WO 03/075663 describe, for example, suitable strobilurin derivatives.
  • the present invention thus relates to the use of strobilurins as medicaments in general and in particular for the treatment and / or prevention of disorders of the iron metabolism in mammals, in particular humans.
  • the invention also relates to the use of strobilurins for the manufacture of a medicament for the treatment and / or prevention of disorders of the iron metabolism.
  • strobilurin derivatives of different structure can be used, according to the invention preferably a strobilurin derivative of the general formula (I) is used.
  • X is halogen, C 1 -C 4 -alkyl or trifluoromethyl
  • B is phenyl, naphthyl, 5-membered or 6-membered hetaryl or 5-membered or 6-membered heterocyclyl containing one to three N atoms and / or one O or S atom or one or two O- and / or S Atoms, wherein the ring systems are unsubstituted or substituted by one to three radicals R a :
  • R a is cyano, nitro, amino, aminocarbonyl, aminothiocarbonyl, halogen, d- Ce-alkyl, C r C 6 haloalkyl, C r C 6 alkylcarbonyl, C r C 6 alkylsulfonyl, d-C ⁇ -alkylsulfinyl, C 3 - C 6 cycloalkyl, C r C 6 alkoxy C r C 6 haloalkoxy, C r C 6 alkylthio, Ci-C-Ce alkyloxycarbonyl d 6 alkylamino, di-CrC 6 - alkylamino, Ci-Ce-alkylaminocarbonyl , Di-d-Ce-alkylaminocarbonyl, d-
  • R b is cyano, nitro, halogen, amino, aminocarbonyl, aminothiocarbonyl, d- Ce-alkyl, C r C 6 haloalkyl, Ci-Ce-alkylsulfonyl, C r C 6 alkylsulfinyl, C 3 -
  • R ⁇ , R ß hydrogen or C r C 6 alkyl
  • R 1 is hydrogen, cyano, C r C 4 alkyl, C r C 4 haloalkyl, C 3 -C 6 cycloalkyl, C r C 4 alkoxy;
  • R c is cyano, nitro, amino, aminocarbonyl, aminothiocarbonyl, halogen, C r C 6 alkyl, C r C 6 haloalkyl, C r C 6 alkylsulfonyl, C r C 6 -
  • R 3 is hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, where the hydrocarbon radicals of these groups are unsubstituted or substituted by one to three radicals R c .
  • X is halogen, C 1 -C 4 -alkyl or trifluoromethyl
  • n is 0 or 1; preferably 0;
  • B is phenyl, naphthyl, 5-membered or 6-membered hetaryl or 5-membered or 6-membered heterocyclyl containing one to three N atoms and / or one O or S atom or one or two O- and / or S Atoms, wherein the ring systems are unsubstituted or substituted by one to three radicals R a :
  • R a is cyano, nitro, amino, aminocarbonyl, aminothiocarbonyl, halogen, C 6 alkyl, Ci-C 6 haloalkyl, C r C 6 alkylcarbonyl, C r C 6 alkylsulfonyl, Ci-C 6 - alkylsulfinyl, C 3 - C 6 -cycloalkyl, C r C 6 -alkoxy C r C 6 -haloalkoxy, C r C 6 -
  • R b is cyano, nitro, halogen, amino, aminocarbonyl, aminothiocarbonyl, dC 6 alkyl, d-Ce-haloalkyl, C r C 6 alkylsulfonyl, C r C 6 alkylsulfinyl, C 3 -C 6 cycloalkyl, C 6 alkoxy, C r C 6 haloalkoxy, C r C 6 alkoxycarbonyl, C r C 6 alkylthio, C r C6-alkylamino, di-Ci-C6-alkylamino, d-Ce-alkylaminocarbonyl, di-d-d-
  • R ⁇ , R ß hydrogen or C r C 6 alkyl; in particular hydrogen or methyl;
  • R 1 is hydrogen, cyano, C r C 4 alkyl, dC 4 haloalkyl, C 3 -C 6 cycloalkyl, C r C 4 - alkoxy;
  • R 2 is phenyl, phenylcarbonyl, phenylsulfonyl, 5- or 6-membered hetaryl, 5- or 6-membered hetarylcarbonyl or 5- or 6-membered hetarylsulfonyl, where the ring systems are unsubstituted or substituted by one to three radicals R a ,
  • R c is cyano, nitro, amino, aminocarbonyl, aminothiocarbonyl, halogen, C 6 alkyl, C r C 6 alkylsulfonyl, C r C 6 alkylsulfinyl, C r C-Ce-haloalkyl, d-C6 alkoxy, d-
  • Active compounds of the formula (I) in which Q is C (CHCH-OCH 3 ) -COOCH 3 , C (NN-OCH 3 ) -COOCH 3 , C (NN-OCH 3 ) CO-NH-CH 3 or N (-OCH 3 ) -COOCH 3 , in particular C ( N-OCH 3 ) -CO-NH-CH 3 .
  • B in formula (I) are phenyl, pyridyl, pyrimidinyl, triazolyl and pyrazolyl, in particular phenyl or pyridyl.
  • V OCH 3 and NHCH 3 in particular NHCH 3
  • Y is CH and N, in particular N.
  • Preferred active compounds of the formula (I) in which Q is N (-OCH 3 ) -COOCH 3 are the compounds described in the publications WO-A 93/15046 and WO-A 96/01256.
  • Preferred active compounds of the formula (I) in which Q is C (CHCH-OCH 3 ) -COOCH 3 are the compounds described in EP-A 178 826 and EP-A 278 595.
  • Preferred active compounds of the formula (I) in which Q is C (CHCH-CH 3 ) -COOCH 3 are the compounds described in EP-A 280 185 and EP-A 350,691.
  • Preferred active compounds of the formula (I) in which A is -O-B are the compounds described in EP-A-382,375 and EP-A-398,692.
  • V is OCH 3 or NHCH 3
  • Y is N and R a is halogen, CrC 4 - alkyl, Ci-C 4 haloalkyl or C 4 haloalkoxy mean.
  • the invention relates both to the use of a strobilurin derivative for the treatment of acute poisoning, as well as the therapy and prophylaxis of chronically elevated iron levels in mammals, especially chronic human diseases.
  • another active ingredient such as ascorbic acid
  • another active ingredient may be used to treat and / or prevent iron metabolism disorders.
  • the invention also relates, quite generally, to a medicament containing at least one strobilurin derivative, in particular a compound of the formula (I), and pharmaceutically suitable auxiliaries.
  • a process for the preparation of a medicament containing one or more strobilurins, in particular compounds of the formula (I), is likewise the subject matter of the invention, where the compound of the formula (I) is mixed with a pharmaceutically suitable auxiliary and this mixture is converted into a form suitable for administration.
  • the invention also relates to pharmaceutically acceptable salts of strobilurins.
  • Pharmaceutically acceptable salts are often particularly suitable for medical applications because of their higher water solubility over the basic compounds. These salts have a pharmaceutically acceptable anion or cation.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are e.g. Salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphorus, metaphosphoric, nitric and sulfuric acid and organic acids such.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphorus, metaphosphoric, nitric and sulfuric acid and organic acids such.
  • acetic acid benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric.
  • Suitable pharmaceutically acceptable basic salts are, in particular, ammonium salts, alkali metal salts, in particular sodium and potassium salts, and alkaline earth metal salts, especially magnesium and calcium salts, and salts of trometamol (2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine and ethylenediamine.
  • physiologically functional derivative refers to any physiologically acceptable derivative of a compound of the invention, e.g. an ester which, when administered to a mammal, e.g. the mouse, rat or human, is capable of directly or indirectly forming compounds of formula (I) or an active metabolite thereof.
  • physiologically functional derivatives which are also the subject of the invention, also include so-called prodrugs of the compounds according to the invention, as described, for example, by H. Okada et al. in Chem. Pharm. Bull. 1994, 42, 57-61.
  • prodrugs can be metabolized in vivo to a compound of the invention.
  • These prodrugs may or may not be effective.
  • the compounds of the invention may also often be in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds of the invention are the subject of the invention.
  • the amount of compound of the invention required to achieve the desired biological effect depends on several factors, e.g. The selected strobilurin compound, the mammal to be treated (eg, mouse or human), the intended use (eg, nature of the poisoning), the mode of administration, and the age, sex, and clinical condition of the patient.
  • the human daily dose ranges from 1 mg to 100 mg (preferably from 3 mg to 80 mg) per day per kilogram of body weight.
  • An intravenous dose may e.g. in the range of 1 mg to 50 mg / kg, e.g. can also be administered as an infusion of 0.05 mg to 5 mg per kilogram per minute. Suitable infusion solutions for these purposes may e.g. from 0.01 mg to 10 mg per milliliter. Single doses may e.g. from 1 mg to 1000 mg of the active ingredient. Thus, for example, ampoules for injections may contain from 10 mg to 1000 mg.
  • oral single-dose formulations such as tablets or capsules, for example, from 1 to 2000 mg, typically from 50 to 1000 mg of the active compound may be employed.
  • the strobilurins in particular the compounds of the formula (I) themselves, can be used as compound, but they are preferably in the form of a pharmaceutical composition or preparation with an acceptable excipient.
  • the excipient must be compatible, d. H. it must be compatible with the other components of the composition and must not be harmful to the patient.
  • the excipient can z. B. is a solid and / or a liquid and is preferably formulated with the active compound as a single dose, for example as a tablet, which may contain from 0.05% to 95 wt .-% of the active ingredient.
  • compositions according to the invention can be prepared by known methods.
  • the active ingredient and pharmacologically acceptable excipients are mixed intensively and then brought into the desired shape.
  • Particularly suitable pharmaceutical compositions according to the invention are those which are suitable for oral and peroral (eg sublingual) and parenteral (eg subcutaneous, intramuscular or intravenous) administration, but also those which are preferred for rectal or topical administration.
  • the invention also relates to coated formulations and sustained-release formulations.
  • a preferred embodiment of the invention relates to acid and gastric juice-resistant formulations.
  • Suitable enteric coatings comprise, for example, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and / or anionic polymers of methacrylic acid and / or methyl methacrylate.
  • Suitable pharmaceutical preparations for oral administration may be in separate units, for example capsules, lozenges or tablets, each containing a certain amount of the compound of formula (I). They can also be in the form of powders or granules, as a solution or suspension in an aqueous or nonaqueous liquid. A formulation as an oil-in-water or water-in-oil emulsion is also possible.
  • compositions may be prepared by any suitable pharmaceutical method comprising a step of contacting the active ingredient and the excipient, which may also consist of several constituents.
  • compositions are prepared by uniformly and homogeneously mixing the active ingredient with the liquid and / or finely divided solid adjuvant, after which the product is molded, if necessary, and then packaged.
  • a tablet may be prepared by compressing or molding a powder or granule of the active compound, optionally with one or more additional excipients.
  • Compressed tablets may be prepared by tableting the compound in free-flowing form such as a powder or granules, optionally mixed with a binder, lubricants, thinners and / or dispersing agents in a suitable machine.
  • molded Tablets may also be prepared by molding the powdered active compound moistened with a liquid diluent in a suitable machine.
  • compositions for peroral administration are e.g. Lozenges containing a compound according to formula (I) with a flavor, usually sucrose and gum arabic, and lozenges containing the compound in an inert base such as gelatin and glycerine or sucrose and gum arabic.
  • Suitable pharmaceutical compositions for parenteral administration are preferably sterile aqueous preparations of strobilurins, especially compounds of formula (I), which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously. Administration may also be by subcutaneous, intramuscular or intradermal injection. These preparations may preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with the blood of the recipient. Injectable compositions according to the invention generally contain from 0.1 to 5% by weight of the active ingredient.
  • Suitable pharmaceutical compositions for rectal administration are, for example, as single-dose suppositories, the preparation of which is known to the person skilled in the art in principle.
  • Suitable pharmaceutical compositions for topical application to the skin are in particular ointment, cream, lotion, paste, spray, aerosol or oil.
  • As adjuvants e.g. Vaseline, lanolin, polyethylene glycols, alcohols and combinations of these substances can be used.
  • the active ingredient is generally present at a level of from 0.1% to 15% by weight of the composition, more preferably from 0.5% to 2%.
  • Transdermal administration is also possible in principle.
  • Suitable pharmaceutical compositions for transdermal applications may be used as a single patch. present, which are suitable for a long-term close contact with the epidermis of the patient.
  • patches contain the active ingredient dissolved in an optionally buffered aqueous solution and / or dispersed in an adhesive or dispersed in a polymer gradually releasing the drug.
  • a suitable drug concentration is z. From 1% to 35%, preferably from about 3% to 15%.
  • the strobilurins have beneficial effects on iron metabolic disorders. Among other things, they influence the excretion of iron via the bile and the stool and reduce the absorption of iron. In particular, they reduce the level of iron in the body (and in the blood) and are suitable for the prevention and treatment of excess iron.
  • the compounds according to the invention can be administered alone or in combination with one or more further pharmacologically active substances which, for example, likewise have beneficial effects on iron metabolic disorders or disorders associated therewith.
  • Dimoxystrobin according to IUPAC nomenclature (E) -2 (methoximino) -N-methyl-2- [ ⁇ - (2,5-xylyloxy) -o-tolyl] acetamide and also oryastrobin, according to IUPAC (2E), have proven particularly suitable.
  • the first group was treated with no iron compound and no strobilurin derivative.
  • the second group was treated with only 200 mg of the phenylacetic acid derivative orysastrobin (as a suspension via gavage).
  • the third group received a single intramuscular injection of 50 mg / kg of iron (III) hydroxide-dextran complex (Myofer ® 100), 1 ml of the injection solution 320 mg of the complex contained (corresponding to 195 mg Fe (OH) 3).
  • the fourth group received both an injection of 50 mg / kg of the iron complex and after 6 hours a dose of 200 mg / kg of the strobilurin derivative by gavage.
  • the fifth group received both an injection of 50 mg / kg of the iron complex and after 24 hours a dose of 200 mg / kg of the strobilurin derivative by gavage.
  • mice In order to detect the therapeutic effect of the abovementioned compounds in disturbed iron metabolism, the following experiments were carried out with a special mouse strain, wherein the mice have a mutation in the HFE gene.
  • HFE mice This genetic defect causes HFE mice to have elevated liver iron levels, which can serve as a model for human hemochromatosis disease.
  • the HFE mice used in the experiments were 12 to 23 weeks old (obtained from University College London, Department of Biochemistry and Molecular Biology).
  • the housing conditions of the mice corresponded to typical standards, as also described in Example 1.
  • both studies with male HFE mice, as well as with female HFE mice were performed.
  • One group of animals each received 2000 ppm of the phenylacetic acid derivative orysastrobin over a period of 7 days.
  • the product was regularly fed through the diet.
  • the comparison group received only regular food.
  • mice showed serum iron levels averaging 40.06 ⁇ mol / l iron after one week.
  • the first group consisted of 3 week old rats. She received only regular nutrition throughout the trial period.
  • the second group also consisted of 3 week old rats.
  • the animals received 500 ppm daily (milligrams of test substance per kilogram of body weight) of dimo-xystrobin. The supply took place via the food.
  • the third group consisted of 6 week old rats that did not receive any active ingredient through the diet.
  • the fourth group consisted of 6 week old rats fed 500 ppm dimoxystrobin daily.
  • the fifth group consisted of 3 week old rats that received no drug.
  • the sixth group consisted of 3 week old rats receiving 250 ppm of the test substance dimoxystrobin daily.
  • the fifth group (control group of young rats) showed an iron level of 96.7 ⁇ mol / l after 2 days and of 96.1 ⁇ mol / l after 7 days.
  • mice C57BL / 6 J Rj, Center d'Elevage R. Janvier, France.
  • mice The housing conditions of the mice corresponded to typical standards. In the experiments, studies were carried out with male mice. In each case a group of animals received daily orally over a period of 7 days Strobilurin. The product was regularly fed through the diet. The comparison group received only regular food.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de dérivés de strobilurine pour le traitement et/ou la prévention de troubles du métabolisme du fer chez les mammifères.
EP07727390A 2006-03-29 2007-03-27 Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer Withdrawn EP2001555A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07727390A EP2001555A1 (fr) 2006-03-29 2007-03-27 Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111933 2006-03-29
EP07727390A EP2001555A1 (fr) 2006-03-29 2007-03-27 Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer
PCT/EP2007/052917 WO2007113170A1 (fr) 2006-03-29 2007-03-27 Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer

Publications (1)

Publication Number Publication Date
EP2001555A1 true EP2001555A1 (fr) 2008-12-17

Family

ID=38284013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07727390A Withdrawn EP2001555A1 (fr) 2006-03-29 2007-03-27 Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer

Country Status (16)

Country Link
US (1) US20100234366A1 (fr)
EP (1) EP2001555A1 (fr)
JP (1) JP2009531379A (fr)
KR (1) KR20080111021A (fr)
CN (1) CN101448550A (fr)
AR (1) AR060178A1 (fr)
AU (1) AU2007233829A1 (fr)
BR (1) BRPI0710209A2 (fr)
CA (1) CA2646209C (fr)
CL (1) CL2007000836A1 (fr)
EA (1) EA200801940A1 (fr)
IL (1) IL194159A0 (fr)
MX (1) MX2008012317A (fr)
TW (1) TW200812592A (fr)
WO (1) WO2007113170A1 (fr)
ZA (1) ZA200809192B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290745B1 (ko) 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
MX2021015385A (es) 2019-06-28 2022-01-24 Procter & Gamble Composiciones antiinflamatorias sinergicas.
EP4171755A1 (fr) 2020-06-26 2023-05-03 The Procter & Gamble Company Compositions anti-inflammatoires synergiques
US11701316B2 (en) 2020-12-18 2023-07-18 The Procter & Gamble Company Synergistic anti-inflammatory compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33989A (en) * 1861-12-24 Improvement it machines for punching boiler-plates
US37873A (en) * 1863-03-10 Improvement in hay-presses
US37839A (en) * 1863-03-03 Improved spoke-machine
DE3623921A1 (de) * 1986-07-16 1988-01-21 Basf Ag Oximether und diese enthaltende fungizide
DE3705389A1 (de) * 1987-02-20 1988-09-01 Basf Ag Substituierte crotonsaeureester und diese enthaltende fungizide
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3823991A1 (de) * 1988-07-15 1990-02-15 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeureester und fungizide, die diese verbindungen enthalten
DE3905911A1 (de) * 1989-02-25 1990-08-30 Basf Ag Neue ss-methoxyacrylate, ihre herstellung und verwendung
PH11991042549B1 (fr) * 1990-06-05 2000-12-04
DE59109047D1 (de) * 1990-06-27 1998-10-08 Basf Ag O-Benzyl-Oximether und diese Verbindungen enthaltende Pflanzenschutzmittel
DE4030038A1 (de) * 1990-09-22 1992-03-26 Basf Ag Ortho-substituierte phenylessigsaeureamide
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
JP3883566B2 (ja) * 1992-01-29 2007-02-21 ビーエーエスエフ アクチェンゲゼルシャフト カルバメートおよびそれらを含む作物保護剤
DE4318917A1 (de) * 1993-06-07 1994-12-08 Bayer Ag 2-Oximino-2-phenyl-acetamide
EP0741694B1 (fr) * 1994-02-04 2003-04-02 Basf Aktiengesellschaft Derives d'acide acetique phenylique, leur procede de preparation, produits intermediaires a cet effet et agents les contenant
EP0945431A3 (fr) * 1994-02-04 2004-08-18 Basf Aktiengesellschaft Procédé et intermédiaires pour la préparation de dérivés de l'acide phénylacétique
DE4423612A1 (de) * 1994-07-06 1996-01-11 Basf Ag 2-[(Dihydro)pyrazolyl-3'-oxymethylen]-anilide, Verfahren zu ihrer Herstelung und ihre Verwendung
DE19539324A1 (de) * 1995-10-23 1997-04-24 Basf Ag Phenylessigsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und sie enthaltende Mittel
US6084120A (en) * 1997-07-09 2000-07-04 Hoffmann-La Roche Inc. β-Alkoxyacrylates against malaria
IT1303688B1 (it) * 1998-11-02 2001-02-23 Medidom Lab Derivati aromatici e relativi complessi di fe(iii) atti all'usocome agenti normalizzanti del livello di ferro nell'organismo.
WO2001046114A1 (fr) * 1999-12-21 2001-06-28 Geltex Pharmaceuticals, Inc. Methode de preparation de hbed
NZ534978A (en) * 2002-03-11 2006-03-31 Basf Ag Method for immunizing plants against bacterioses
DE10211428A1 (de) * 2002-03-15 2003-10-23 Bayer Ag Bekämpfung von Parasiten an Tieren durch Halogenpyrimidine
EP1523310A2 (fr) * 2002-07-09 2005-04-20 The Scripps Research Institute Procede pour empecher les lesions par ischemie et reperfusion
US20050032903A1 (en) * 2003-08-08 2005-02-10 Suarez-Cervieri Miguel Octavio Method for controlling fungal sieases in legumes
KR100624238B1 (ko) * 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007113170A1 *

Also Published As

Publication number Publication date
CL2007000836A1 (es) 2008-05-23
WO2007113170A1 (fr) 2007-10-11
MX2008012317A (es) 2008-10-10
AU2007233829A1 (en) 2007-10-11
CA2646209A1 (fr) 2007-10-11
ZA200809192B (en) 2010-01-27
US20100234366A1 (en) 2010-09-16
BRPI0710209A2 (pt) 2011-05-24
CA2646209C (fr) 2011-08-16
JP2009531379A (ja) 2009-09-03
IL194159A0 (en) 2011-08-01
KR20080111021A (ko) 2008-12-22
AR060178A1 (es) 2008-05-28
TW200812592A (en) 2008-03-16
EA200801940A1 (ru) 2009-04-28
CN101448550A (zh) 2009-06-03

Similar Documents

Publication Publication Date Title
EP0128482B1 (fr) Formes galéniques d'antidiabétiques orales et procédé de leur préparation
DE4345199C2 (de) Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
EP0128483B1 (fr) Formes galéniques d'antidiabétiques orales et procédé de leur préparation
DE60118172T2 (de) Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
EP1978949B1 (fr) Préparation combinée destinée à améliorer la qualité du sperme
DE2523998A1 (de) Pharmazeutische zubereitung fuer die behandlung der schizophrenie
DE69922787T2 (de) N,n'-bis(2-hydroxybenzyl)ethylendiamin-n,n'-diessigsäure und natriumsalze davon zur eisenchelatierungstherapie
EP2001555A1 (fr) Utilisation de strobilurine pour le traitement de troubles du metabolisme du fer
DE19858789A1 (de) Kombination von Cerivastatin und Fibraten
DE60313886T2 (de) Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Behandlung von Obesitas
EP2558084B1 (fr) Combinaison du vitamin k et de l'amide nicotinique pour l'utilisation dans des maladies qui impliquent une calcification extra-osseuse
DE2349538C2 (de) Arzneimittel zur Behandlung von Lebererkrankungen
DE69907387T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis.
DE2712777A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper
EP1064002A1 (fr) Utilisation de sphingosine-1-phosphate, de derives de sphingosine-1-phosphate et/ou de leurs melanges pour traiter les maladies inflammatoires cutanees
DE2625053C3 (de) Arzneimittel zur Kontrolle von Leberkrankheiten
EP0450123A1 (fr) Composition pharmaceutique pour application topique contenant du diclofenac-sodium
AT412447B (de) Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
AT392002B (de) Verwendung von peroxydiphosphaten zur herstellung von pharmazeutischen tabletten bzw. pharmazeutischen waesserigen loesungen
EP2818167A1 (fr) Composition pharmaceutique antivirale active
DE60117472T2 (de) Pharmazeutische zusammensetzung zur behandlung von fettleibigkeit
EP0291751B1 (fr) Préparation pharmaceutique constituée par un mélange
DE2502679C3 (de) Phenoxyalkancarbonsäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE2336176A1 (de) Nahrungs- und futtermittelzusatz und verfahren zu seiner herstellung
DE2312134A1 (de) Anthelmintikum

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: RS

17Q First examination report despatched

Effective date: 20110725

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: STROBILURINS FOR TREATING MALFUNCTIONS OF THE IRON METABOLISM

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20081029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120926